CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee 3D Printing and Heart Failure: The Present and the Future Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T

Clinical Trial2014 Sep 11;371(11):993-1004.

JOURNAL:N Engl J Med. Article Link

Angiotensin–neprilysin inhibition versus enalapril in heart failure

McMurray JJ, Packer M, PARADIGM-HF Investigators and Committees. Keywords: angiotensin receptor-neprilysin inhibitor LCZ696; enalapril; HFrEF; mortality; survival; hospitalization for heart failure

FULL TEXT PDF